Semaglutide ASCVD cost model

A 2026 US simulation found that lifetime semaglutide treatment could add 1.31 quality-adjusted life-years for people with obesity and established atherosclerotic cardiovascular disease, or ASCVD, but at a median incremental cost of $118,996 per quality-adjusted life-year gained. That exceeded the model's stated $100,000 threshold. The result is a price finding, not a finding that the medicine lacks cardiovascular benefit^[1].

What the model actually tested

This was not another randomized trial. The researchers built a decision model around records from 519,566 US veterans with stable ASCVD, obesity defined as a body mass index above 30 kg/m2, and no type 2 diabetes. Their mean age was 65. Eight percent were Black and 4% were female. Hospital admissions supplied annual rates of heart attack and stroke, while the National Death Index supplied mortality data^[1]. Those demographics make the input cohort large, but much less representative of women than the broader population that may meet the treatment indication.

The model then applied cardiovascular hazard ratios from SELECT, the clinical trial behind semaglutide's cardiovascular evidence in adults with overweight or obesity and existing cardiovascular disease but no diabetes. SELECT randomly assigned 17,604 people to weekly semaglutide 2.4 mg or placebo. A major cardiovascular event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over a mean 39.8 months, giving a hazard ratio of 0.80^[2]. The new paper therefore combines observed veteran event rates with treatment effects estimated in a different population.

Researchers projected annual movement among health states for 35 years, discounted future costs and health at 3% per year, and ran 1,000 Monte Carlo iterations. Those iterations vary uncertain inputs to show how the result changes across plausible values. The primary case assumed full adherence to semaglutide for life and kept its annual cost at $14,000 throughout the model^[1]. Both assumptions deserve attention because they drive the headline number.

The projected gains and costs

Under the lifetime treatment case, projected quality-adjusted survival rose from 9.72 to 11.03 quality-adjusted life-years, or QALYs. A QALY combines time alive with a value assigned to health during that time. Projected health care costs rose from $130,853 to $302,821 per patient. Dividing the extra cost by the extra QALYs produced the median incremental cost-effectiveness ratio, or ICER, of $118,996 per QALY gained^[1]. An ICER is a comparison tool for health policy. It is not a price quote, a prediction of one patient's bill, or a measure of whether treatment works biologically.

The same model projected 10% fewer heart attacks and 7% fewer deaths over ten years relative to the baseline arm. These are simulated outcomes, not events observed after assigning veterans to treatment. The clinical anchor remains SELECT, which directly observed fewer major cardiovascular events but also found that adverse events led to permanent treatment discontinuation in 16.6% of participants receiving semaglutide and 8.2% receiving placebo^[2]. That difference between projection and observation is central to reading the new report.

Adherence changed the answer

The authors also tested a less idealized pattern: 30% discontinuation in year one, followed by 5% discontinuation each year for the rest of the first decade. Projected benefit fell to 0.7 QALY over 35 years, and the ICER rose to $124,523 per QALY gained^[1]. The paper calls those health gains very minimal. More precisely, they were smaller than in the full-adherence case while costs remained high enough to worsen the value ratio.

Price was the other decisive input. At $14,000 per year, the paper reported that semaglutide needed a willingness-to-pay threshold above about $130,000 per QALY to become preferable to current care. Its figure caption says the probability of cost-effectiveness passed 50% at $123,000, so the text and figure do not give one identical crossing point. For an ICER below $100,000 per QALY, the model required annual drug cost below $10,000^[1].

Why another model found a higher ratio

A separate 2026 JAMA Cardiology analysis projected an ICER of $148,100 per QALY for secondary cardiovascular prevention, despite using a lower annual semaglutide cost of $8,604. It estimated 358,400 major cardiovascular events prevented among about 4 million eligible US adults and $23 billion in added annual health spending. At a $120,000 threshold, that model required the annual price to fall to $7,055^[3].

The two estimates are not interchangeable. The veteran study used event rates from an older cohort with BMI above 30 and then applied SELECT hazard ratios. The JAMA model represented US adults aged 45 or older with BMI of at least 27 and a history of heart attack or stroke. They also used different simulation structures, cost inputs, and eligibility definitions^[1][3]. Agreement on the direction matters more than the apparent precision: both papers projected health gains, and both found that US price assumptions strongly determined the value result.

What the paper cannot settle

The new model assumes a constant drug price for 35 years and imports published estimates for costs and health-state utilities. It cannot model changing obesity trajectories or the combined effect of other preventive treatments. Its primary case also assumes perfect lifetime adherence, even though SELECT recorded more treatment discontinuation with semaglutide than placebo^[1][2]. Future negotiated prices, rebates, patent changes, and real persistence could all move the ICER.

The analysis also does not decide whether semaglutide is appropriate for an individual. The FDA label includes reduction of major cardiovascular event risk in adults with established cardiovascular disease and overweight or obesity, but it remains a prescription medicine with contraindications and warnings that require clinical assessment^[4]. The semaglutide regulation section covers its legal status in the markets we track. Treatment and coverage questions belong with the relevant clinician and payer.

The useful takeaway

This paper does not overturn SELECT. It asks what SELECT's cardiovascular effect might be worth when mapped onto a high-risk US veteran cohort for decades. In that simulation, semaglutide added quality-adjusted life, but a fixed annual price of $14,000 pushed the ICER above the study's $100,000 benchmark^[1]. Its cleanest message is not that prevention failed. It is that a credible projected health gain can still be difficult to fund at scale when long-term drug cost and persistence are uncertain.